Viatris (VTRS) revenue: $14.3B
Viatris reported $14.3B of revenue for the year ended Dec 31, 2025, down 3.0% from $14.7B a year earlier.
From Viatris's filings with the SEC · Read the filing · VTRS stock page
Viatris revenue by year
#327 of 3,622 US companies by revenue · See the full ranking
| Year ended | Revenue | Change |
|---|---|---|
| Dec 31, 2025 | $14.3B | -3% |
| Dec 31, 2024 | $14.7B | -4% |
| Dec 31, 2023 | $15.4B | -5% |
| Dec 31, 2022 | $16.3B | -9% |
| Dec 31, 2021 | $17.9B | – |
Revenue of similar companies
Companies in the same industry as Viatris, by SEC industry code, with the closest revenue. Each name opens the same page for that company.
| Company | Revenue, latest year | Year ended |
|---|---|---|
| TEVA Pharmaceutical Industries | $17.3B | Dec 31, 2025 |
| Regeneron Pharmaceuticals | $14.3B | Dec 31, 2025 |
| Viatris | $14.3B | Dec 31, 2025 |
| Vertex Pharmaceuticals Inc / Ma | $12B | Dec 31, 2025 |
| Bausch Health Companies | $10.3B | Dec 31, 2025 |
| Zoetis | $9.5B | Dec 31, 2025 |
| Organon | $6.2B | Dec 31, 2025 |
Questions and answers
What is Viatris's revenue?
Viatris reported $14.3B of revenue for the year ended Dec 31, 2025, down 3.0% from $14.7B a year earlier.
Numbers as reported in Viatris's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology